nivolumab,relatlimab
bms
['relativity-047', 'melanoma']
 presents new relativity-047 data. pfs hr 0.78 os hr 0.80. good to be both lag3 and pd1 pos. impressive 30% orr in mucosal and acral #melanoma no diff by braf status. #asco22 
Associate professor in Surgery at Sahlgrenska University Hospital. @sahlgrenska @SahlgrenskaAcad @goteborgUni #wcmtm #melanoma #breastcancer #surgery